A Phase I-II Trial Using Dendritic Cells Transduced With An Adenoviral Vector Containing The p53 Gene To Immunize Patients With Extensive Stage Small Cell Lung Cancer After Standard Chemotherapy
Phase of Trial: Phase I/II
Latest Information Update: 08 May 2014
At a glance
- Drugs INGN 225 (Primary) ; Carboplatin; Etoposide
- Indications Small cell lung cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 14 Jan 2014 Planned End Date changed from 1 Feb 2014 to 1 Aug 2014, according to ClinicalTrials.gov record.
- 13 Sep 2013 Planned end date changed from 1 Aug 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.